Pfizer Inc. (PFE) Reports Q3 Revenue of $16.6B, Raises 2026 Guidance

What happened

Pfizer reported third-quarter 2026 revenue of $16.6B, down $71 million and relatively flat year over year. Revenue excluding Comirnaty and Paxlovid grew 7% operationally, launched and acquired products grew 32%, and Pfizer raised its 2026 revenue and adjusted diluted earnings-per-share guidance.

Confirmed

Global impact / market context

Raised full-year guidance suggests Pfizer expects better results than previously forecast, while growth outside COVID-19 products may reduce reliance on those sales. However, higher research and development spending, up 18% operationally, can raise near-term costs as the company develops oncology and obesity treatments.

Analyst inference

The quarter combines nearly unchanged total revenue with stronger growth in non-COVID products and launched or acquired products. Because the revised guidance figures and the contribution from those newer products are not provided, investors cannot assess the scale of the expected improvement from this information alone.

Analyst inference

What to watch

1. Look for Pfizer’s revised 2026 revenue and adjusted earnings-per-share guidance figures; the article says they were raised but does not provide the new targets. Confirmed
2. Track whether growth excluding Comirnaty and Paxlovid continues, since sustained expansion could help offset lower sales of COVID-19 products. Analyst inference
3. Watch research and development spending and later results from oncology and obesity candidates, which could clarify whether higher costs support future product growth. Analyst inference

Evidence

• Original source link unavailable